Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Stereotaxis stock gains as Erasmus Medical adopts Genesis robotic system, marking a milestone in cardiac arrhythmia care.
Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Operator Good afternoon.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.07 per share a year ago.
Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know
Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Stereotaxis: Recurring Revenue Inflection
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin disposables and platform launches fueling a shift to an annuity-like model. Consensus underestimates top-line growth; I model $51M FY26E revenue, supported by robust operating momentum and innovation pipeline.
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
Stereotaxis, Inc. (NYSE:STXS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2025 Earnings Conference Call.
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep will generate significant recurring revenue per procedure and expand the advantages of using robotics in EP.
